Cindy Perettie
Foundation Medicine, a Roche subsidiary, has appointed Cindy Perettie as its CEO effective Feb. 4, replacing Troy Cox. Most recently, Perettie served as senior VP in global oncology product strategy at Roche's oncology unit. Prior to Roche, she acted as president of global development innovations at the Sarah Cannon Research Institute. Perettie has also held a number of positions at Genentech, also a unit of Roche, including VP of global regulatory operations and regional head of Europe, Middle East, and Africa operations and global development.
William Finger
Cancer Genetics has appointed William Finger as its executive VP of precision medicine and biopharma solutions. He will be responsible for developing and overseeing the company's precision medicine and biopharma and clinical trial business unit. Finger has more than 25 years of experience in the life sciences, diagnostics, and lab service industries. Before joining Cancer Genetics, he acted as managing director of precision medicine and diagnostics for Kineticos, a life science consultancy firm. Before Kineticos, Finger spent 12 years at Laboratory Corporation of America, where he held leadership positions in scientific affairs, preclinical services, biorepository, and operations.
Richard Compton
Richard Compton resigned as director of Metrichor, a sister company of Oxford Nanopore Technologies, last month. He was appointed to the firm's board in 2016 and was also general manager at Metrichor. Compton remains VP of commercial operations at Oxford Nanopore. He previously served as VP and general manager of the EMEA region at Illumina.
For more recent items on executive appointments and promotions in the omics and molecular diagnostics industries, please see the People in the News page on our website.